Recombinant Human Anti-IAV HA Antibody (FI6V3) (CAT#: PABL-214)

Figure 1 IC50 measurements with pseudo virus-based microneutralization assay for the IgGs reformatted from the selected anti-HA trimer scFvs.

Chen, C., Chiu, Y. K., Yu, C. M., Lee, C. C., Tung, C. P., Tsou, Y. L.,... & Yang, A. S. (2017). High throughput discovery of influenza virus neutralizing antibodies from phage-displayed synthetic antibody libraries. Scientific reports, 7(1), 14455.

Figure 2 EC50 measurements with ELISA for the IgGs reformatted from the selected anti-HA trimer scFvs.

Chen, C., Chiu, Y. K., Yu, C. M., Lee, C. C., Tung, C. P., Tsou, Y. L.,... & Yang, A. S. (2017). High throughput discovery of influenza virus neutralizing antibodies from phage-displayed synthetic antibody libraries. Scientific reports, 7(1), 14455.

Figure 3 IC50 measurements with pseudo virus-based microneutralization assay for the IgGs reformatted from the selected anti-HA trimer scFvs.

Chen, C., Chiu, Y. K., Yu, C. M., Lee, C. C., Tung, C. P., Tsou, Y. L.,... & Yang, A. S. (2017). High throughput discovery of influenza virus neutralizing antibodies from phage-displayed synthetic antibody libraries. Scientific reports, 7(1), 14455.

Figure 1 Recombinant Human Anti-IAV HA Antibody (PABL-214) in SDS-PAGE

SDS-PAGE analysis of PABL-214 in β-mercaptoethanol-reduced (lane 1) and non-reduced (lane 2) conditions. Gel stained for 30 minutes with Coomassie Blue. As a result of different β-mercaptoethanol-reduced proteins (Heavy chain and Light chain) migrate as about 50 kDa and 25 kDa, respectively. And non-reduced protein migrates as 180 kDa.

Figure 2 Recombinant Human Anti-IAV HA Antibody (PABL-214) in SEC-HPLC

The purity of PABL-214 was greater than 93% as determined by SEC-HPLC.
Column: 3 µm, 7.8 x 300 nm
Mobile phase: 150 mM Sodium Phosphate Buffer, pH 7.0
Detection: UV 280 nm
Injection: 10 µl

Figure 3 Anti-IAV HA Recombinant Antibody (PABL-214) in ELISA

ELISA analysis of PABL-214 was performed by coating with Influenza A H3N2 (A/Perth/16/2009) Hemagglutinin / HA Protein (His Tag). Then blocked with BSA and incubated with PABL-214. The HRP-conjugated goat anti-human IgG as a secondary antibody (1: 2000). Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.

Figure 4 Anti-IAV HA Recombinant Antibody (PABL-214) in ELISA

ELISA analysis of PABL-214 was performed by coating with Influenza A H2N2 (A/Japan/305/1957) Hemagglutinin / HA Protein (His Tag). Then blocked with BSA and incubated with PABL-214. The HRP-conjugated goat anti-human IgG as a secondary antibody (1: 2000). Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.

Figure 5 Anti-IAV HA Recombinant Antibody (PABL-214) in ELISA

ELISA analysis of PABL-214 was performed by coating with Influenza A [A/Hong Kong/483/97 (H5N1)] Hemagglutinin (HA) Protein (His Tag). Then blocked with BSA and incubated with PABL-214. The HRP-conjugated goat anti-human IgG as a secondary antibody (1: 2000). Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.

Figure 6 Anti-IAV HA Recombinant Antibody (PABL-214) in WB

Western blot analysis of PABL-214 was performed with Influenza A H3N2 (A/Perth/16/2009) Hemagglutinin / HA Protein (His Tag) onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with PABL-214 and HRP goat anti-human IgG as a secondary antibody (1: 2000). Chemiluminescent detection was performed.

Lane 1: Reduced antigen (0.8 μg)

Figure 7 Anti-IAV HA Recombinant Antibody (PABL-214) in WB

Western blot analysis of PABL-214 was performed with Influenza A H2N2 (A/Japan/305/1957) Hemagglutinin / HA Protein (His Tag) onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with PABL-214 and HRP goat anti-human IgG as a secondary antibody (1: 2000). Chemiluminescent detection was performed.

Lane 1: Reduced antigen (0.8 μg)

Figure 8 Anti-IAV HA Recombinant Antibody (PABL-214) in WB

Western blot analysis of PABL-214 was performed with Influenza A [A/Hong Kong/483/97 (H5N1)] Hemagglutinin (HA) Protein (His Tag) onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with PABL-214 and HRP goat anti-human IgG as a secondary antibody (1: 2000). Chemiluminescent detection was performed.

Lane 1: Reduced antigen (0.8 μg)

Figure 9 Anti-IAV HA Recombinant Antibody (PABL-214) in DB

Dot Blot analysis of PABL-214 was performed by coating with Influenza A H3N2 (A/Perth/16/2009) Hemagglutinin / HA Protein (His Tag).

PABL-214 incubation concentration: 2 μg/mL.
HRP-conjugated goat anti-human IgG as a secondary antibody (1: 2000)

Figure 10 Anti-IAV HA Recombinant Antibody (PABL-214) in DB

Dot Blot analysis of PABL-214 was performed by coating with Influenza A H2N2 (A/Japan/305/1957) Hemagglutinin / HA Protein (His Tag).

PABL-214 incubation concentration: 2 μg/mL.
HRP-conjugated goat anti-human IgG as a secondary antibody (1: 2000)

Figure 11 Anti-IAV HA Recombinant Antibody (PABL-214) in DB

Dot Blot analysis of PABL-214 was performed by coating with Influenza A [A/Hong Kong/483/97 (H5N1)] Hemagglutinin (HA) Protein (His tag).

PABL-214 incubation concentration: 2 μg/mL.
HRP-conjugated goat anti-human IgG as a secondary antibody (1: 2000)